About longeveron inc - LGVN
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
LGVN At a Glance
Longeveron, Inc.
Life Science & Technology Park
Miami, Florida 33136
| Phone | 1-844-470-2550 | Revenue | 1.20M | |
| Industry | Biotechnology | Net Income | -22,704,000.00 | |
| Sector | Health Technology | Employees | 38 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LGVN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.418 |
| Price to Book Ratio | 2.044 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.229 |
| Enterprise Value to Sales | 4.217 |
| Total Debt to Enterprise Value | 0.163 |
LGVN Efficiency
| Revenue/Employee | 31,552.632 |
| Income Per Employee | -597,473.684 |
| Receivables Turnover | 11.529 |
| Total Asset Turnover | 0.067 |
LGVN Liquidity
| Current Ratio | 1.334 |
| Quick Ratio | 1.334 |
| Cash Ratio | 1.14 |
LGVN Profitability
| Gross Margin | -35.363 |
| Operating Margin | -1,942.202 |
| Pretax Margin | -1,893.578 |
| Net Margin | -1,893.578 |
| Return on Assets | -126.771 |
| Return on Equity | -164.749 |
| Return on Total Capital | -349.346 |
| Return on Invested Capital | -159.019 |
LGVN Capital Structure
| Total Debt to Total Equity | 14.52 |
| Total Debt to Total Capital | 12.679 |
| Total Debt to Total Assets | 8.03 |
| Long-Term Debt to Equity | 2.978 |
| Long-Term Debt to Total Capital | 2.60 |